Clinical Trial Update: ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder [Phase 2]

View source ↗

Summary

Phase 2 study of RDC-0313 (ALKS 33) in adults with Binge Eating Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• RDC-0313 (ALKS 33) (RDC-0313)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Binge Eating Disorder | Phase 2 | Status: COMPLETED